SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator\'s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Epistemonikos ID: 78f7757109123f0ae7e8eff4015c649ed7cfa04d
First added on: Jan 01, 2025